Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
Number of items: 15.

2022

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2020

Christoph, D. C. C., Rizzo, F., Kambartel, K-O., Winke, S., Panse, J., Abdulla, D. S., Scheffler, M., Azeh, I. T., Hoiczyk, M., Turki, A. and Metzenmacher, M. (2020). Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence. Ann. Oncol., 31. S. S876 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Roeth, A., Raiser, C., Panse, J., Steinbach, Cicalo F., Sockel, K., Haferlach, T., Huebel, K., Blau, I. W., Casper, J., Platzbecker, U., Ganser, A., Hoechsmann, B. and Schrezenmeier, H. (2020). Changes in the burden of disease in treated and untreated patients in the German cohort of the International Registry of Paroxysmal Nocturnal Hemoglobinuria (PNH) - a 2020 Update. Oncol. Res. Treat., 43 (SUPPL 4). S. 174 - 175. BASEL: KARGER. ISSN 2296-5262

2019

Biehl, L. M., Higgins, P., Wille, T., Peter, K., Hamprecht, A., Peter, S., Doerfel, D., Vogel, W., Haefner, H., Lemmen, S., Panse, J., Rohde, H., Klupp, E. -M., Schafhausen, P., Imirzalioglu, C., Falgenhauer, L., Salmanton-Garcia, J., Stecher, M., Vehreschild, J. J., Seifert, H. and Vehreschild, M. J. G. T. (2019). Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards. Clin. Microbiol. Infect., 25 (8). S. 1013 - 1021. OXFORD: ELSEVIER SCI LTD. ISSN 1469-0691

2018

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

2017

Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E. and Illerhaus, G. (2017). Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial. Bone Marrow Transplant., 52. S. S96 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Fritsch, K., Kasenda, B., Schorb, E., Hau, P., Bloehdorn, J., Moehle, R., Loew, S., Binder, M., Atta, J., Keller, U., Wolf, H-H, Krause, S. W., Hess, G., Naumann, R., Sasse, S., Hirt, C., Lamprecht, M., Martens, U., Morgner, A., Panse, J., Frickhofen, N., Roeth, A., Hader, C., Deckert, M., Fricker, H., Ihorst, G., Finke, J. and Illerhaus, G. (2017). High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia, 31 (4). S. 846 - 853. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

2016

Biehl, L. M., Huth, A., Panse, J., Kraemer, C., Hentrich, M., Engelhardt, M., Schaefer-Eckart, K., Kofla, G., Kiehl, M., Wendtner, C. -M., Karthaus, M., Ullmann, A. J., Hellmich, M., Christ, H. and Vehreschild, M. J. G. T. (2016). A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients. Ann. Oncol., 27 (10). S. 1916 - 1923. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Schalk, E., Biehl, L. M., Faerber, J., Huth, A., Panse, J., Kraemer, C., Hentrich, M., Engelhardt, M., Schaefer-Eckart, K., Kofla, G., Kiehl, M., Wendtner, C. -M, Karthaus, M., Comely, O. A., Fischer, T. and Vehreschild, M. J. G. T. (2016). Prophylactic exchange of central venous catheters (CVC) for prevention of CVC-related bloodstream infections (CRBSI) in patients with haematological malignancies: indirect evidence from pooled data of the SECRECY registry and the COAT study. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262

2015

Biehl, L. M., Huth, A., Panse, J., Hentrich, M., Engelhardt, M., Schaefer-Eckart, K., Kofla, G., Kiehl, M., Wendtner, C., Karthaus, M., Hellmich, M., Christ, H., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Chlorhexidine containing iv-catheter securement dressings for the prevention of central venous catheter-related bloodstream infections in neutropenic patients: A randomized trial (COAT study). Oncol. Res. Treat., 38. S. 188 - 189. BASEL: KARGER. ISSN 2296-5262

Hoechsmann, B., Leichtle, R., Roeth, A., Panse, J., Haferlach, T., Borchmann, P., Aulitzky, W. E., Dengler, J., Port, M., Platzbecker, U., Klausmann, M., Steinmetz, T., Becker, M., Schmidt, B. and Schrezenmeier, H. (2015). Data from German centers in the global PNH Patient Registry-analysis of the translation of the DGHO-guidelines for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in real life therapy. Oncol. Res. Treat., 38. S. 105 - 107. BASEL: KARGER. ISSN 2296-5262

2014

Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Heukamp, L., Koenig, K., Serke, M., Nogova, L., Toepelt, K., Stoelben, E., Engel-Riedel, W., Randerath, W., Kaminsky, B., Panse, J., Zander, T., Buettner, R. and Wolf, J. (2014). Clinical and Molecular Characteristics of Non-Small Cell Lung Cancer Patients Harboring PIK3CA Mutations. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

This list was generated on Tue Jul 16 14:35:04 2024 CEST.